Advertisement

Antiepileptika

  • Ulrich Schwabe

Zusammenfassung

Auffällig ist das kontinuierlich steigende Verordnungsvolumen der neueren Antiepileptika, die inzwischen fast doppelt so häufig wie traditionelle Antiepileptika (z. B. Valproinsäure, Carbamazepin, Phenytoin) verordnet werden. Das früher führende Carbamazepin hat in den letzten 10 Jahren um fast 40% abgenommen. Die Verordnungen von Valproinsäure stagnieren. Levetiracetam ist 2013 zu dem führenden Antiepileptikum aufgestiegen. Weitere häufig verordnete Vertreter der neueren Antiepileptika sind Lamotrigin, Gabapentin und Pregabalin.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. for the Gabapentin Diabetic Neuropathy Study Group (1998): Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 280: 1831–1836Google Scholar
  2. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD (2007): Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308–1317PubMedGoogle Scholar
  3. Beydoun A (1999): Monotherapy trials with gabapentin for partial epilepsy. Epilepsia 40 (Suppl 6): S1–3–S16Google Scholar
  4. Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, Kerr D (2012): Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 35: 2451–2458PubMedCentralPubMedCrossRefGoogle Scholar
  5. Brodie MJ (2004): Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45 Suppl 6: 19–27PubMedGoogle Scholar
  6. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ (2007): Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402–408PubMedCrossRefGoogle Scholar
  7. Bundesministerium für Gesundheit (2013): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Perampanel vom 7. März 2013 veröffentlicht 7. März 2013, BAnz AT 26.03.2013 B–4Google Scholar
  8. Carmichael K, Pulman J, Lakhan SE, Parikh P, Marson AG (2013): Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013 Dec 19; 12: CD001416Google Scholar
  9. Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, Vaz-Carneiro A (2011): Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 52: 1280–1291Google Scholar
  10. Devinsky O (2011): Sudden, unexpected death in epilepsy. N Engl J Med 365: 1801–1811PubMedCrossRefGoogle Scholar
  11. Dooley M, Plosker GL (2000): Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 60: 871–893PubMedGoogle Scholar
  12. Eisai (2013): Eisai setzt vorübergehend den Vertrieb des innovativen Antiepileptikums Fycompa ® (Perampanel) in Deutschland aus. Internet: http://www.presseportal.de/pm/64962/2500257/
  13. European Medicines Agency (2004): Europäischer öffentlicher Beurteilungsbericht (EPAR) Lyrica. Scizentific discussion. Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/lyrica/084504en6.pdf
  14. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee (2004): Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45: 401–409Google Scholar
  15. Gamble CL, Williamson PR, Marson AG (2006): Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev 25 (1):CD00103–1Google Scholar
  16. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T (2006): ILAE Treatment Guidelines: Evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47: 1094–1120CrossRefGoogle Scholar
  17. Goa KL, Ross SR, Chrisp P (1993): Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152–176PubMedGoogle Scholar
  18. Hitiris N, Brodie MJ (2006): Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 19: 175–180PubMedGoogle Scholar
  19. Holmes D (2012): NICE epilepsy guidance „may be detrimental to patient care“. Lancet 379: 39–9CrossRefGoogle Scholar
  20. Kassenärztliche Bundesvereinigung (2007): Wirkstoff AKTUELL. Pregabalin (Lyrica® Hartkapseln). Internet: www.kbv.de/publikationen/116.html
  21. Koch MW, Polman SK (2009): Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009 Oct 7; (4):CD00645–3Google Scholar
  22. Kwan P, Sander JW (2004): The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 75: 1376–1381PubMedCentralPubMedCrossRefGoogle Scholar
  23. LaRoche SM, Helmers SL (2004): The new antiepileptic drugs: scientific review. JAMA 291: 605–614Google Scholar
  24. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004): The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS 101: 9861–9866Google Scholar
  25. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DS, Smith PEM, Tudor Smith C, Vanoli A, Williamson PR, on behalf of the SANAD Study group (2007a): The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369: 1000–1015Google Scholar
  26. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DS, Smith PEM, Tudor Smith C, Vanoli A, Williamson PR, on behalf of the SANAD Study group (2007b): The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet 369: 1016–1026Google Scholar
  27. Mbizvo GK, Dixon P, Hutton JL, Marson AG (2012): Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012 Sep 12; 9: CD00190–1Google Scholar
  28. McCorry D, Chadwick D, Marson A (2004): Current drug treatment of epilepsy in adults. Lancet Neurol 3: 729–735PubMedCrossRefGoogle Scholar
  29. Milburn-McNulty P, Powell G, Sills GJ, Marson AG (2014): Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev. 2014 Mar 9; 3: CD01006–2Google Scholar
  30. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ (2009): Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009 Jul 8; (3): CD00707–6Google Scholar
  31. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA (1999): Randomized double- blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159: 1931–1937PubMedCrossRefGoogle Scholar
  32. National Institute for Health and Clinical Excellence (NICE) (2012): The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. January 2012, NICE clinical guideline 137. Internet: www.nice.org.uk/page.aspx- ? o=CG020NICEguidelineGoogle Scholar
  33. Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH (2013): Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline. Neuropsychiatr Dis Treat 9: 467–476PubMedCentralPubMedGoogle Scholar
  34. Perucca E, Yasothan U, Clincke G, Kirkpatrick P (2008): Lacosamide. Nat Rev Drug Discov 7: 973–974PubMedCrossRefGoogle Scholar
  35. Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG (2014): Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Feb 25; 2: CD00141–7Google Scholar
  36. Shorvon SD (2009): Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959–2009. Epilepsia 50 Suppl 3: 93–130PubMedGoogle Scholar
  37. Steinhoff BJ (2014): Efficacy of perampanel: a review of pooled data. Epilepsia 55 Suppl 1: 9–12Google Scholar
  38. Tomson T, Battino D (2012): Teratogenic effects of antiepileptic drugs. Lancet Neurol 11: 803–813Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Ulrich Schwabe

There are no affiliations available

Personalised recommendations